Status:
RECRUITING
Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique
Lead Sponsor:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Conditions:
HIV
HIV Antiretroviral Therapy (ART) Adherence
Eligibility:
All Genders
18+ years
Brief Summary
The HIV infection not fully controlled, despite being under antiretroviral treatment, could make virus resistance against the antiretroviral treatments, making hardest the well control of HIV infectio...
Detailed Description
This research study consists of a single visit, in which you will be taken an additional vial of blood to analyze the presence or absence of mutations in your virus to HIV drugs. In addition, other HI...
Eligibility Criteria
Inclusion
- Patients able to understand and sign the informed consent form.
- Documented HIV-1 infection.
- Under the first line TLD for at least 6 months.
- At least 3 months follow-up with CV \>200c/ml.
Exclusion
- Patients \<18 years of age.
- Under the first line regime other than TLD.
- Patients with active neoplastic processes.
- Patients with active opportunistic diseases.
- Patients unable to give informed consent.
Key Trial Info
Start Date :
October 25 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06607588
Start Date
October 25 2024
End Date
September 1 2026
Last Update
May 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Carmelo
Chokwé, Mozambique, F2C3+JPR